• Vaccines.

    Johnson & Johnson does not ensure 55 million doses to the EU

  • Ema meets March 11 for Johnson & Johnson vaccine

  • Usa, Biden: vaccines for all Americans by May.

    Agreement between Merck and Johnson & Johnson's

  • Usa, FDA experts green light to Johnson & Johnson single-dose vaccine

  • Vaccine Johnson & Johnson: "It covers the variants and no recall is needed"

Share

March 09, 2021 "In line with our agreement with the European Commission, Johnson & Johnson remains committed to supplying 200 million doses of its Janssen Covid-19 vaccine in 2021, starting in the second quarter."



This was specified in a note by J&J also relaunched by the communication from Palazzo Chigi, noting how the US company has downsized the news of the cut in doses planned for Europe in the next quarter, while still guaranteeing the commitment to supply 200 million doses to the EU in 2021, starting from the second quarter.



"To achieve our ambitious goals of supplying our COVID-19 vaccine, since early 2020 we have focused on building a global supply network in parallel with the development of our vaccine," explains J&J.



"We continue to initiate and activate new production sites as quickly as possible. We recognize this is an extremely complex challenge, for us and for all other vaccine manufacturers. We work with our partners, regulators and governments to accelerate all steps in the vaccine manufacturing process and to activate our manufacturing sites as soon as health authorities permit. Our current production plans will enable us to reach one billion doses per year by the end of 2021. Johnson & Johnson is committed to making its nonprofit Covid-19 vaccine available for use in the event of an emergency pandemic, "he concludes.



Palazzo Chigi

The Johnson & Johnson company with a note tonight downsized the news of the cut in doses planned for Europe in the next quarter, while still guaranteeing the commitment to supply 200 million doses to the EU in 2021, starting from the second quarter .



"As far as Italy is concerned - it is emphasized at Palazzo Chigi - in the period from 8 March to 3 April a total of about 6.5 million doses will be supplied. In the second quarter, on the other hand, in Italy there will be a sharp increase in the doses available. , for a total amount of over 36.8 million doses for Pfizer, AstraZeneca and Moderna ".



Giorgetti-Breton phone call

The Minister for Economic Development, Giancarlo Giorgetti, had a telephone conversation with the European Commissioner, Thierry Breton, on the subject of the European strategy on the production of anti-Covid vaccines.

The phone call follows the meeting that Giorgetti and Breton had in Rome last Thursday.

Commissioner Breton, who heads the European Vaccines Task Force, has confirmed the commitments on the European production levels of vaccines and on the expectations of strong growth in the coming months that will allow the majority of the European population to be vaccinated.



Giorgetti confirmed the willingness of Italian companies to be actively included in the production cycle of vaccines already approved by the EMA and AIFA.



Alalrme downsized

Johnson & Johnson had told the European Union it had supply problems that could complicate plans to supply 55 million doses of its coronavirus vaccine in the second quarter of the year. 



The spokesman responsible for health of the EU Commission had indicated that Brussels "is in contact with all vaccine developers to ensure delivery of sufficient quantities on schedule in line with the commitments undertaken by the companies". 



The way to approval

J & J's vaccine, which requires only one dose, is expected to be approved on March 11 by the EMA.

The company has pledged to supply 200 million doses to the European Union by 2021. J&J began rolling out its vaccine in the United States this month, with a goal of delivering 100 million doses by the end of May. but it has nearly halved its delivery forecast for March to 20 million doses while increasing new production facilities.



An internal document from the German Ministry of Health and a program published by the Italian Ministry of Health on 3 March confirm that under the contract with the European Union, J&J had committed to deliver around 55 million doses in the second quarter, of which approximately 10 million to Germany and 7.3 million to Italy.

Supplies are expected to double in the third quarter, as the two programs show, but J&J has yet to provide data on planned deliveries.